Cytokines and coronary artery disease: The state of the art

Critical Pathways in Cardiology

Volumn 7, Issue 2, 2008, Pages 139-151

  El Menyar, Ayman A ^a,b  

^a HAMAD GENERAL HOSPITAL   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Atherosclerosis; Cytokine; Inflammatory markers; Interleukin; Myocardial ischemia; Revascularization; Tumor necrosis factor

Indexed keywords

ABCIXIMAB; BIOLOGICAL MARKER; CD40 LIGAND; CYCLOOXYGENASE 2; GAMMA INTERFERON; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEXELIZUMAB; PROSTAGLANDIN E2; RAPAMYCIN; SCAVENGER RECEPTOR; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CELL DEATH; CELL PROLIFERATION; CEREBROSPINAL FLUID; CHEMOTAXIS; COLLAGEN SYNTHESIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID OXIDATION; MEDLINE; MONOCYTE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPERFUSION; RESTENOSIS; REVIEW; SILENT MYOCARDIAL ISCHEMIA; TH1 CELL; TH2 CELL; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; CORONARY DISEASE; CYTOKINES; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 67650214970     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e31816713d9     Document Type: Review

References (174)

1. Lowe GDO. Haemostatic risk factors for arterial and venous thrombosis. In: Poller L, Ludlam CA, eds. Recent Advances in Blood Coagulation, 7 ed. Edinburgh, UK: Churchill Livingstone; 1997:69-96.
2. Meade TW. Fibrinogen measurement to assess the risk of arterial hrombosis in individual patients: yes. J Thromb Haemost. 2005;3: 32-634.
3. Lowe GDO. Fibrinogen measurement to assess the risk of arterial hrombosis in individual patients: not yet. J Thromb Haemost. 2005;3:635-637.
4. Koenig W, Rosenson RS. Acute-phase reactants and coronary heart isease. Semin Vasc Med. 2002;2:417-428.
5. Woodward M, Lowe GDO, Francis L, et al. On behalf of the ADET Study Investigators. A randomised comparison of the ffects of aspirin and clopidogrel on thrombotic risk factors and -reactive protein following myocardial infarction. JThromb Hae-most. 2004;2:1934-1940.
6. Lip GYH, Blann AD, Farooqi IS, et al. Sequential alterations in aemorheology, endothelial dysfunction, platelet activation and hrombogenesis in relation to prognosis following acute stroke: the est Birmingham Stroke Project. Blood Coagul Fibrinolysis. 2002;13:339 -347.
7. Barber M, Langhorne P, Rumley A, et al. Hemostatic function and rogressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004;35:1421-1425.
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. irculation. 2002;105:1135-1143.]
9. Jude B, Zawadzki C, Susen S, Corseaux D. Relevance of tissue factor n cardiovascular disease. Arch Mal Coeur Vaiss. 2005;98:667-671.
10. Tedgui A, Mallat Z. Mecanismes inflammatoires et antiinflammatoires dans la paroi vasculaire. In: Pinet F, Babuty D, Carrier L, Duperray A,Grynberg A, Loirand G, Samuel JL, eds. Biologie et pathologie du coeur et des vaisseaux. Paris: Medecine-Science/Flammarion; 2002;395-407.
11. Alam SE, Nasser SS, Fernainy KE, et al. Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol. 2004;4:166 -170.
12. Waehre T, Halvorsen B, Damas JK, et al. Inflammatory imbalance between IL-10 and TNF-a in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest. 2002;32:803-810. ]
13. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost. 2002;88:554-567.
14. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1b decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656 -660.
15. Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease,interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation. 2001;103:947-953.
16. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA.2001;286:2107- 2113.
17. Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw. 2000;11:153-160.
18. Tedgui A, Mallat Z. Interleukin-10: an anti-atherogenic cytokine? EurJ Clin Invest. 2001;31:1-2.
19. Hsieh MY, Chen WY, Jiang MJ, et al. IL-20 promotes angiogenesis in a direct and indirect manner. Genes Immunology. 2006;7:234-242.
20. Wei CC, Hsu YH, Li HH, et al. IL-20: biological functions and clinical implications. J Biomed Sci. 2006;13:601-612.
21. Stouthard JML, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996;76:738-742.
22. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between lasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695.
23. Boekholdt SM, Peters RJ, Hack CE, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterio-scler Thromb Vasc Biol. 2004;24:1503-1508.
24. Wuttge DM, Eriksson P, Sirsjo A, et al. Expression of interleukin-15 in mouse and human atherosclerotic lesions. Am J Pathol. 2001;159:417-423.
25. Ross R. The pathogenesis of atherosclerosis: a perspective for the1990s. Nature. 1993;362:801-809.
26. Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. JEndocrinol. 2003;177:351-355.
27. Behre CJ, Fagerberg B, Hulten LM, Hulthe J. The reciprocal association of adipocytokines with insulin resistance and C-reactive protein inclinically healthy men. Metabolism. 2005;54:439 -444.
28. Heeschen C, Dimmeler S, Hamm CW, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N EnglJ Med. 2003;348:1104-1111.
29. Gupta S, Pablo AM, Jiang X, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752-2761.
30. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41:37S-42S.
31. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J. 1999;20:1039 -1043.
32. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of inter-leukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079-2084.
33. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.
34. Cosin-Sales J, Christiansen M, Kaminski P, et al. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosin- ophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation. 2004;09:1724-1728.
35. Avanzas P, Arroyo-Espliguero R, Quiles J, et al. Elevated serum neopterin predicts future adverse events in patients with chronic stable angina pectoris. Eur Heart J. 2005;26:457-463.
36. Berrahmoune H, Lamont J, Fitzgerald P, Visvikis-Siest S. Inter-individual variation of inflammatory markers of cardiovascular risks and diseases.Clin Chem Lab Med. 2005;43:671-684.
37. Pantsulaia I, Trofimov S, Kobyliansky E, Livshits G. Genetic and environmental influences on IL-6 and TNF-alpha plasma levels in apparently healthy general population. Cytokine. 2002;19:138-146.
38. Ouyang Y, Virasch N, Hao P, et al. Suppression of human IL-1beta, IL-2, IFN-7, and TNF-alpha production by cigarette smoke extracts. J Allergy Clin Immunol. 2000;106:280-287.
39. McKay A, Komai-Koma M, MacLeod KJ, et al. Interleukin-18 levelsin induced sputum are reduced in asthmatic and normal smokers. Clin Exp Allergy. 2004;34:904-910.
40. Burgess JL, Nanson CJ, Hysong TA, et al. Rapid decline in sputum IL-10 concentration following occupational smoke exposure. InhalToxicol. 2002;14:133-140.
41. Steptoe A, Willemsen G, Owen N, et al. Acute mental stress elicits delayed increases in circulating inflammatory cytokine levels. Clin Sci(Lond). 2001;101:185-192.
42. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation healthy subjects and in type 2 diabetic patients: role fat andcarbohydrate meals. J Am Coll Cardiol. 2002;39:1145-1150.
43. Straczkowski M, Dzienis-Straczkowska S, Stepien Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations areincreased in obese subjects and related to fat mass and tumor necrosisfactor-alpha system. JClin Endocrinol Metab. 2002;87:4602-4606.
44. Escobar-Morreale HF, Botella-Carretero JI, Villuendas Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab. 2004;89:806-811.
45. Corica F, Allegra A, Buemi M, et al. Reduced plasma concentrations of transforming growth factor beta1 (TGF-beta1) in obese women. Int JObes Relat Metab Disord. 1997;21:704-707.
46. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol.2001;37:440.
47. Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998;98:800.
48. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Potential implications for inflammation and plaque instability. Circulation. 2000;101:1372.
49. Moser R, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin-1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest. 1989;83:444-455.
50. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony stimulating factor production in human arterial smooth muscle. Atherosclerosis. 1993;99:241-252.
51. Balbay Y, Tikiz H, Baptiste RJ, et al. Circulating interleukin-1 beta,nterleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 inpatients with chronic stable angina and myocardial infarction. Angiol-ogy. 2001;52:109-114.
52. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
53. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstableangina. Circulation. 1998;98:2370 -2376.
54. Manten A, de-Winter RJ, Minnema MC, et al. Procoagulant and pro-inflammatory activity in acute coronary syndromes. Cardiovasc Res. 1998;40:389-395.
55. Futterman LG, Lemberg L. High-sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events. Am JCrit Care. 2002;11:482-486.
56. Krishnaswamy G, Kelley J, Yerra L, et al. Human endothelium as a source of multifunctional cytokines: molecular regulation and possiblerole in human disease. J Interferon Cytokine Res. 1999;19:91-104.
57. Aggarwal BB. Signalling pathways of the TNF superfamily: a double edged sword. Nat Rev Immunol. 2003;3:745-756.
58. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk oforonary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
59. Campbell LA, Nosaka T, Rosenfeld ME, et al. Tumor necrosis factor alpha plays a role in the acceleration of atherosclerosis by Chlamydia pneumoniae in mice. Infect Immun. 2005;3164-3165.
60. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15-26.
61. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
62. Kinlay S, Schwartz GG, Olsson AG, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after anacute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386-391.
63. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-1052.
64. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem. 1995;270:9558-9563
65. Lacraz S, Nicol LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96:2304-2310.
66. Lindmark E, Tenno T, Chen J, Siegbahn A. IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood. Br J Haematol. 1998;102:597-604.
67. Terkeltaub RA. IL-10: an "immunologic scalpel" for atherosclerosis? Arterioscler Thromb Vasc Biol. 1999;19:2823-2825.
68. Pinderski Oslund LJ, Hedrick CC, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Atheroscler Thromb Vasc Biol.1999;19:2847-2853.
69. Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 inadvanced human atherosclerotic plaques. Arterioscler Thromb VascBiol. 1999;19:611-616.
70. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the anti inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109-2114.
71. Chalikias GK, Tziakas DN, Kaski JC, et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a1-year follow-up in patients with acute coronary syndrome. Int JCardiol. 2007;117:333-339.
72. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 inhuman atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603.
73. Gerdes N, Sukhova GK, Libby P, et al. Expression of interleukin(IL)-18 and functional IL-18 receptor on human vascular endothelialcells, smooth muscle cells, and macrophages: implications for athero-genesis. J Exp Med. 2002;195:245-257.
74. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-7. Circ Res. 2002;90:E34-E38.
75. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin- 18binding protein signaling modulates atherosclerotic lesion developmentand stability. Circ Res. 2001;89:E41-E45.
76. Barbaux SC, Blankenberg S, Rupprecht HJ, et al. Association between P-selectin gene polymorphisms and soluble P-selectin levels and theirrelation to coronary artery disease. Arterioscler Thromb Vasc Biol.2001;21:1668- 1673.
77. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost. 2007;97:714-721.
78. Kraaijeveld AO, de Jager SC, van Berkel TJ, et al. Chemokines andatherosclerotic plaque progression: towards therapeutic targeting. CurrPharm Des. 2007;13:1039-1052.
79. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med.2004;36:98-118.
80. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40.
81. Simeoni E, Winkelmann BR, Hoffmann MM, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:1438-1446.
82. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962-971.
83. Chalikias GK, Tziakas DN, Kaski JC, et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronarysyndrome. Atherosclerosis. 2005;182:135-143.
84. Mills R, Bhatt DL. The Yin and Yang of arterial inflammation. JAmColl Cardiol. 2004;44:50 -52.
85. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001;88:877-887.
86. Mallat Z, Henry P, Alouani S, et al. Increased plasma concentrations ofinterleukin-18 in acute coronary syndromes. Heart. 2002;88:467-469.
87. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the anti inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001;104:746 -749.
88. Tziakas DN, Chalikias GK, Kaski JC, et al. Inflammatory and anti inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis. 2007;193:196-203.
89. Yamashita H, Shimada K, Seki E, et al. Concentrations ofinterleukins, interferon and C-reactive protein in stable and unstable angina pectoris.Am J Cardiol. 2003;91:133-136.
90. Fichtlscherer S, Breuer S, Heescen C, et al. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary arterydisease. JAm Coll Cardiol. 2004;44:44-49.
91. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
92. Prediman K, Shah PK. Circulating markers of inflammation for vascular risk prediction. Circulation. 2000;101:1758-1759.
93. Woolf CJ, Allchorne A, Safieh-Garabedian B, et al. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumor necrosis factor-alpha. Br J Pharmacol. 1997;121:417- 424.
94. Watkins LR, Wiertelak BP, Goehier LB, et al. Characterization of cytokine-induced hyperalgesia. Brain Res. 1994;654:15-26.
95. Porreca F, Lai J, Malan TP. Can inflammation relieve pain? Nat Med.1998;4:1359-1360.
96. Oka T, Aou S, Hori H. Intracerebrovascular injection of interleukin-1-beta enhances nociceptive neuronal responses of the trigeminalnucleus caudalis in rats. Brain Res. 1994;656:236 -244.
97. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997;20:252-258.
98. Baeurle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141-179.
99. Opree A, Kress M. Involvement of the inflammatory cytokines TNF-a, IL-1-beta and IL-6 but not IL-8 in the development of heat hyperalge-sia: effects of heat-evoked CGRP release from rat skin. J Neurosci.2000;20: 6289-6293.
100. Welters ID, Fimiani C, Bilfinger TV, et al. NF-KB, nitric oxide and opiate signaling. Med Hypotheses. 2000;54:263-268.
101. Wood JN. Regulation of NF-kappa B activity in rat dorsal root ganglia and PC12 cells by tumor necrosis factor and nerve growth factor. Neurosci Lett. 1995;192:41-44.
102. Poole S, Cunha FQ, Selkirk S, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol. 1995;115:684-688.
103. Mazzone A, Cusa C, Mazzucchelli I, et al. Increased production of inflammatory cytokines in patients with silent myocardial ischemia.JAm Coll Cardiol. 2001;38:1895-1901.
104. Mazzone A, De Servi S, Vezzoli M, et al. Plasma levels of interleukin 2, 6, and 10 phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis. 1999;45:369-374.
105. Hoffmeister A, Rothenbacher D, Kunze M, et al. Prognostic value of inflammatory markers alone and in combination with blood lipids inpatients with stable coronary artery disease. Eur J Intern Med. 2005;16:47-52.
106. Fisman EZ, Benderly M, Esper RJ, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol. 2006;98:14-18.
107. Zoellner H, Filonzi EL, Stanton HR, et al. Human arterial smooth muscle cells synthesize granulocyte colony- stimulating factor in re-sponse to interleukin-1b and tumor necrosis factor-alpha. Blood. 1992;80:2805-2810.
108. Majno G, Joris J. Apoptosis, oncosis and necrosis. An overview of cell death. Am J Pathol. 1995;146:3-15.
109. Myllarniemi M, Calderon L, Lemstrom K, et al. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 1997;11:1119-1126.
110. Hansson GK, Jonasson L, Holm J, et al. Interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and invitro. Circ Res. 1988;63:712-719.
111. Mehra VC, Ramgolam VC, Bender JR. Cytokines and cardiovascular disease. JLeukoc Biol. 2005;78:805-818.
112. Moreno PR, Bernardi VH, Lopez-Cuellar, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94:3090-3097.
113. Taubman MB. Tissue factor regulation in vascular smooth muscle: a summary of studies performed using in vivo and in vitro models.Am JCardiol. 1993;72, 55C-60C.
114. Schonbeck U, Mach F, Sukhova GK, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am JPathol. 2000;156,7-14.
115. Amento E, Ehsani N, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in humanvascular smooth muscle cells. Arterioscler Thromb. 1991;11:1223-1230.
116. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy. 2003;2:257-265.
117. Simon AD, Yazdani S, Wang W, et al. Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina versus stable angina. J Thromb Thrombolysis. 2000;9:217-222.
118. Koukkunen H, Penttila K, Kemppainen A, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med. 2001;33:37-47.
119. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17:699-706.
120. Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J.2002;144:811-817.
121. Kilic T, Ural D, Ural E, Yumuk Z, Agacdiken A, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart. 2006;92:1041-1046.
122. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum Schomig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748-755.
123. Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty andd effects of pexelizumab, a C5 inhibitor: a substudy ofthe COMMA trial.Eur Heart J. 2005;26:1964-1970.
124. Kohsaka S, Menon V, Lowe AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165:1643-1650.
125. Pietila K, Harmoinen A, Hermens W, et al. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus anpen infarct-related coronary artery after thrombolytic therapy. EurHeartJ. 1993;14:915-919.
126. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492-1498.
127. Yasuda M, Akioka K, Teragaki M, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156 -163.
128. Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97-103.
129. Nijmeijer R, Lagrand WK, Lubbers YT, et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol.2003;163:269-275.
130. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab. Ananti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angio-plasty (COMMA) trial. Circulation. 2003;108:1184-1190.
131. de Zwaan C, Kleine AH, Diris JC, et al. Continuous 48- h C1-inhibitortreatment, following reperfusion therapy, in patients with acute myo-cardial infarction. Eur Heart J. 2002;23:1670-1677.
132. Shernan SK, Fitch JC, Nussmeier NA, et al. Impact of pexelizumab, ananti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004;77:942-949.
133. The APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. A randomized controlled trial. JAMA. 2007;297:43-51.
134. Berthonneche C, Sulpice T, Boucher F, et al. New insights into the pathological role of TNF-a in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am JPhysiol Heart Circ Physiol. 2004;287:H340-H350.
135. Monden Y, Kubota T, Tsutsumi T, et al. Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction. Cardiovas Res. 2007;73:794-805.
136. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med.1999;5:1135- 1142.
137. Gaspardone A, Crea F, Versaci F, et al. Predictic value of C-reactive protein after successful coronary artery stenting in patients with stableangina. Am J Cardiol. 1998;82:515-518.
138. Versaci F, Gaspardone A, Tomai F. Predictic value of C-reactiverotein in patients with unstable angina undergoing coronary stentimplantation. Am JCardiol. 2000;85:92-95.
139. Hadjadj S, Cloutier I, Geoffroy P, et al. Stent implantation in coronary porcine arteries is associated with early activation of TNF-a andTNF-a receptor II expression. Atherosclerosis. 2007;192:25-32.
140. Gottsauner-Wolf M, Zasmeta G, Hornykewycz M, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J.2000;21:1152-1158.
141. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003;89:218 -224.
142. Versaci F, Gaspardone G. Prevention of restenosis after stenting: The emerging role of inflammation. Coron Artery Dis. 2004;15:307-311.
143. Li JJ. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses. 2004;62:499-506.
144. Kozinski M, Krzewina-Kowalska A, Kubica J, et al. Percutaneous coronary intervention trigger a systemic inflammatory response in patients treated for in-stent restenosis: comparison with stable and unstable angina. Inflamm Res. 2005;54:187-193.
145. Jian-Jun Li, Shao-Ping Nie, Chao-Yang Zhang, et al. Is inflammation a contributor for coronary stent restenosis? Med Hypotheses. 2007;68:945-951.
146. Hojo Y, Ikeda U, Katsuki T, et al. Interleukin-6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 2000;84:83-87.
147. Inoue T, Uchida T, Yaguchi I, et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation. 2003;107:1757-1763.
148. Karas SP, Gravanis MB, Santoian EC, et al. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis, JAm Coll Cardiol. 1992;20:467-474.
149. Monraats PS, Kurreeman FA, Pons D, et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun. 2007;8:44-50.
150. Yazdani S, Simon AD, Vidhun R, et al. Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions. Am Heart J. 1998;136:357-361.
151. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
152. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferationafter implantation of sirolimus-coated stents in human coronary arter ies: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
153. Ma KL, Ruan XZ, Powis SH, et al. The anti-atherosclerotic effects ofirolimus on human vascular smooth muscle cells. Am JPhysiol HeartCirc Physiol. 2007;292:H2721-H2728.
154. Goetze S, Xi XP, Kawano Y, et al. TNF-alpha-induced migration ofvascular smooth muscle cells is MAPK dependent. Hypertension.1999;33:183-189.
155. Javed Q, Swanson N, VohraH, etal. Tumornecrosis factor-alphaantibody eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture. ExpMol Pathol. 2002;73:104-111.
156. Youssef AA, Chang LT, Hang CL, et al. Level and value of interleukin-18 in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J. 2007;71:703-708.
157. Yip HK, Youssef AA, Chang LT, et al. Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronaryintervention. Circ J. 2007;71:1086 -1091.
158. Yip HK, Wu CJ, Chang HW, et al. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest. 2005;127:1491-1497.
159. Funayama H, Ishikawa SE, Kubo N, et al. Close association ofregional interleukin-6 levels in the infarct-related culprit coronary artery with restenosis in acute myocardial infarction. Circ J. 2006;70:426 -429.
160. Segev A, Kassam S, Buller CE, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary an- giographic restenosis after elective stenting. Eur Heart J. 2004;25:1029 -1035.
161. Dibra A, Mehilli J, Braun S, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. AmHeart J. 2005;150:344-350.
162. Hong YJ, Jeong MH, Park OY, et al. The role of C-reactive protein on the long-term clinical outcome after primary or rescue percutaneous coronary intervention. Korean JIntern Med. 2003;18:29 -34
163. Caixeta AM, Brito FS, Jr, Costa MA, et al. Enhanced inflammatory response to coronary stenting marks the development of clinically relevant restenosis. Catheter Cardiovasc Interv. 2007;69:500-507.
164. Kubica J, Kozinski M, Krzewina-Kowalska A, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int JMol Med. 200516:173-180.
165. Brunette ND, Munno I, Pellegrino PL, et al. Inflammatory cytokine imbalance after coronary angioplasty: links with coronary atherosclerosis. J Interven Cardiol. 2007;20:248 -257.
166. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutane ous coronary revascularisation. Circulation. 2001;104:163-167.
167. Bonz AW, Lengenfelder B, Jacobs M, Strotmann J. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J. 2003;145:693-699.
168. Misoph M, Babin-Ebell J. Interindividual variations in cytokine levels following cardiopulmonary bypass. Heart Vessels. 1997;12:119-127.
169. Hennein HA, Ebba H, Rodriguez JL, Merrick SH, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 1994;108:626-635.
170. Deliargyris EN, Raymond RJ, Theoharides TC, et al. Sites of interleu- kin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am JCardiol. 2000;86:913-918.
171. Wan S, DeSmet JM, Barvais L, Goldstein M, et al. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1996;112:806-811.
172. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
173. Finkelman F, Morris S, Orekhova T, Sehy D. The in vivo cytokine capture assay for measurement of cytokine production in the mouse. Current Protocols Immunol. 2003;6:28.
174. Favre N, Bordmann G, Rudin W. Comparison of cytokine measurements using ELISA, ELISPOT and semi-quantitative RT-PCR.JImmunol Methods. 1997;204:57-66.